A new study looks at an antibody that could help remyelination in multiple sclerosis.
GeNeuro recently announced that it has finished enrolling multiple sclerosis (MS) patients in the CHANGE-MS Phase 2b study — several months ahead of schedule. The company now expects to report topline results in mid- to late autumn rather than at year’s end.
“Completing enrollment in CHANGE-MS several months sooner than previously anticipated is a significant achievement for our GNbAC1 development program and, most importantly, accelerates the timeline to potentially provide MS patients with a new and effective therapeutic option,” GeNeuro’s CEO, Jesús Martin-Garcia, said in a news release.
The CHANGE-MS (NCT02782858) study is evaluating the effect of GNbAC1 on 260 patients with relapsing-remitting multiple sclerosis (RRMS). Patients were enrolled at multiple clinical sites across Europe.
Its goal is to evaluate whether GNbAC1 can reduce RRMS patients’ active brain lesions — assessed through magnetic resonance imaging (MRI) — at six months and one year after treatment, compared to placebo.
Read full article: Phase 2 Multiple Sclerosis Study Fully Enrolled, Results Now Due in Fall
|Read Full Article: Phase 2 Multiple Sclerosis Study Fully Enrolled, Results Now Due in Fall|